RxDoctor Payments Data

Syed Moin, MD

Internal Medicine · Newburgh, NYNPI 1447335351

Payments from drug & device makers

$2,130in general payments, 2019–2025

Across 121 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$357
  • Boehringer Ingelheim$213
  • Novo Nordisk$189
  • GSK$188
  • Johnson & Johnson$159
  • Novartis$144
  • plus $880 from 17 others

What the payments were for

  • Food & beverage$2,123100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$67,775
Medicare patients
53
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$11,065
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$10,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,686
JardianceEmpagliflozin13$9,370
JanuviaSitagliptin Phosphate12$6,762
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,136
Janumet XrSitagliptin Phos/Metformin Hcl13$4,724
Roflumilast11$893
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen54$736
Albuterol Sulfate HfaAlbuterol Sulfate25$592
Fluticasone Propionate49$511
Triazolam15$489
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$478
Rosuvastatin Calcium18$426
Alprazolam101$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$188$14,82324 claims
MerckJanuvia, Janumet Xr$79$11,48625 claims
Novo NordiskOzempic$189$11,06512 claims
Boehringer IngelheimJardiance$213$9,37013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Newburgh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →